-
Hyperactivity In La Jolla Pharma Shares As Hypotension Treatment Aces Late-Stage Trial
Monday, February 27, 2017 - 5:07pm | 490The capriciousness associated with the biotech space is in the forefront once again with the near doubling in the shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) on Monday. The shares were on a high in reaction to positive trial results of its treatment option for hypotension. The...
-
Kate Spade Looking Into Strategic Alternatives, Including Selling Itself
Thursday, February 16, 2017 - 12:16pm | 377Shares of apparel and fashion maker Kate Spade & Co (NYSE: KATE) jumped more than 10 percent on Thursday after the company confirmed what media reports have been suggesting over the past few months, namely the company is exploring a sale of itself. A Bloomberg report dated December 29, 2016,...
-
Americans Value Financial Stability More Than Looks, Physical Fitness
Saturday, February 11, 2017 - 2:28pm | 444There may be more to attraction than meets the eye... at least in the United States. Ahead of Valentines Day, SunTrust Banks, Inc. (NYSE: STI) found in online study that 41 percent of Americans consider financial stability to be among the traits they find most important in a partner. “People...
-
Wall Street Consensus On Twitter: Sell The Stock
Friday, February 10, 2017 - 12:03pm | 356Shares of Twitter Inc (NYSE: TWTR) continued trading lower on Friday after Thursday's disappointing earnings report resulted in a more than 10 percent selloff in the stock. 14 Voices From The Street Here is a roundup of the mostly unanimous bearish outlook from Wall Street's top analysts following...
-
What's The Takeout Rate For Kate Spade?
Friday, December 30, 2016 - 2:20pm | 326Since reports of Kate Spade & Co (NYSE: KATE) exploring sale emerged, the market is abuzz with speculations over the price at which the handbag maker shouldsell itself. SunTrust expects a takeout price in the range of $18-$23 per share after analyzing recent similar deals. The brokerage...
-
Kroger: Intriguing Play Ahead Of Third-Quarter Report
Wednesday, November 30, 2016 - 11:52am | 241The nation's largest traditional grocery chain, Kroger Co(NYSE: KR) has had a difficult year amid a deflationary food price environment. Share prices have declined nearly 20 percent in 2016, meaning it could be an appropriate time to take a closer look. Barclays views Kroger as “best-in-class...
-
Bob Peck Reviews A Record Singles' Day For Alibaba
Saturday, November 12, 2016 - 4:14pm | 160Alibaba Group Holding Ltd (NYSE: BABA) Singles' Day on was undoubtedly a hit, raking in nearly $18 billion in gross merchandise value. Singles' Day is now the world’s largest online shopping event and bigger than Black Friday. Alibaba’s Singles' Day haul grew 32 percent...
-
Comeback Story Of The Year? SunTrust Initiates Hostess At Buy On First Day Of Trading
Monday, November 7, 2016 - 1:03pm | 370Just four years ago, Hostess Brands Inc. (NASDAQ:TWNK) was in a dire situation. Fans rushed to stock up on Twinkies thinking they would no longer be around for much longer following the company's Chapter 7 bankruptcy filing. The 86-year-old brand was eventually bought out of liquidation and...
-
Analysts Continue To Press 'Like' On Facebook
Friday, November 4, 2016 - 9:21am | 322A day after Facebook Inc (NASDAQ: FB) delivered strong third-quarter results and offered a soft outlook for the year 2017, different brokerages have come out with their opinions. However, there is not much change in the analysts’ perception, who continued to press the “like”...
-
Bob Peck Reiterates $142 Facebook Target, Says It Has Long Runway
Thursday, November 3, 2016 - 9:54am | 306SunTrust’s Bob Peck reiterated his Buy rating and $142 target price on Facebook Inc(NASDAQ: FB) even as investors weigh forward commentary of a “meaningful” revenue deceleration and “significant” investments. Facebook said ad loads would be less of a driver going...
-
Looking Beyond Q3, Twitter's Q4 Could 'Make Or Break' The Company
Tuesday, October 25, 2016 - 5:08pm | 335Twitter Inc (NYSE: TWTR) stock has been all over the map in 2016 as wave after wave of buyout rumors has come and gone. However, with buyout chatter dying down for the most part, SunTrust analyst Robert Peck believes the company’s Q3 earnings report and management commentary could provide...
-
Who (If Anybody) Is Still Looking To Purchase Twitter?
Tuesday, October 25, 2016 - 10:37am | 474Twitter Inc (NYSE: TWTR) is seeking to address fundamental weakness with some drastic measures. If a report that appeared in Bloomberg is to be believed, the company may soon announce plans to eliminate 8 percent (about 300 individuals) of its workforce. SunTrust, in a research note...
-
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Thursday, October 20, 2016 - 1:57pm | 557Drug pricing has been one of the hot topics of the year. As Citron Research's controversial executive editor Andrew Left said last month, “Regulating the price of pharmaceuticals and eliminating price gouging might be the only issue that Trump and Hillary both agree on.” Conversing...
-
More Analysts Neutral On Valvoline As Shares Down From Post-IPO Highs
Tuesday, October 18, 2016 - 2:06pm | 291Valvoline Inc (NYSE: VVV) celebrated its debut into the public market with its IPO late September of this year. Since then, the stock has traded between $22.60 and $24.51, lower by 0.6 percent since debut. Currently, the stock is down more than 6 percent from the high. For those brokerages covering...
-
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
Tuesday, October 18, 2016 - 1:32pm | 879Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has had a bad year, with its stock down more than 49 percent. However, analysts have noted the company has plenty of potential in the non-alcoholic steatohepatitis (NASH) space, where there are still no FDA-approved therapies. Back in April, Logribel...